Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MYCITE KIT vs SEDAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Management of moderate to moderately severe pain where an opioid analgesic is required
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
The terminal elimination half-life is approximately 4-6 hours in adults with normal renal function. In patients with creatinine clearance <30 m L/min, the half-life may be prolonged to 10-15 hours, requiring dose adjustment.
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Hydrocodone is metabolized primarily via CYP3A4 and CYP2D6 to hydromorphone and other metabolites. Acetaminophen is metabolized primarily via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a hepatotoxic metabolite (NAPQI) that is normally detoxified by glutathione.
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose. Hepatic metabolism to inactive metabolites, followed by biliary and fecal elimination, accounts for the remaining 30-40%. Less than 5% is excreted unchanged in feces.
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
Approximately 92-95% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
Volume of distribution is 0.8-1.2 L/kg, indicating extensive distribution into total body water and tissues. Higher Vd is observed in obesity (up to 1.5 L/kg).
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
Oral: 75-85% due to first-pass metabolism. Intramuscular: 90-100%. Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
GFR 30-50 m L/min: Use with caution, maximum 4 tablets per day. GFR <30 m L/min: Contraindicated due to butalbital accumulation.
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%, maximum 3 tablets per day. Child-Pugh C: Contraindicated.
Not approved for patients <18 years; safety and effectiveness not established.
Not recommended for patients under 12 years of age.
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
Initiate at lowest effective dose (1 tablet every 6 hours); monitor for excessive sedation and cognitive impairment.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
Addiction, Abuse, and Misuse: SEDAPAP exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and monitor regularly. Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely, especially during initiation and dose titration. Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can cause fatal overdose. Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening. Cytochrome P450 3A4 Interaction: Concomitant use with CYP3A4 inhibitors may increase hydrocodone levels and prolong adverse effects. Concomitant use with CYP3A4 inducers may decrease efficacy. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Concomitant use may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; severe hypotension; adrenal insufficiency; hepatotoxicity (due to acetaminophen); opioid-induced hyperalgesia; withdrawal; risks of use in patients with head injuries, impaired consciousness, or increased intracranial pressure; use in patients with gastrointestinal conditions including paralytic ileus; use in patients with severe renal or hepatic impairment; use in elderly, cachectic, or debilitated patients; use in patients with pulmonary disease; use in patients with biliary tract disease; use in patients with acute pancreatitis; use in patients with CNS depression; use in patients with toxic psychosis; use in patients with known or suspected surgical abdomen; use in patients with urinary retention; use in patients with prostatic hypertrophy; use in patients with urethral stricture; use in patients with hypothyroidism; use in patients with Addison's disease; use in patients with kyphoscoliosis; use in patients with severe obesity; use in patients with seizures or seizure disorders; use in patients with substance abuse history; driving and operating machinery; use in pregnancy; use in lactation.
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Hypersensitivity to hydrocodone, acetaminophen, or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy.
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
Avoid alcohol. Take with food or milk to reduce gastrointestinal irritation. High-fat meals may delay absorption but not clinically significant. No specific food restrictions.
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities, cardiac defects, developmental delay), neonatal hemorrhage due to vitamin K deficiency (valproate), and withdrawal syndrome. Acetaminophen carries minimal risk.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
Both valproate and acetaminophen are excreted into breast milk. Valproate M/P ratio approximately 0.05-0.1; infant serum levels low but potential for hepatotoxicity and thrombocytopenia. Acetaminophen M/P ratio ~1.0, considered safe in therapeutic doses. Caution advised with valproate; monitor infant for jaundice, bruising, and sedation.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
Valproate: Dose may need reduction due to increased clearance (plasma levels decrease 30-50% in late pregnancy); monitor serum levels and adjust to maintain therapeutic concentration. Acetaminophen: No dose adjustment required in pregnancy; standard dosing recommended.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
SEDAPAP is a combination product containing an opioid (codeine or hydrocodone) and acetaminophen. Avoid exceeding 3 grams/day of acetaminophen to prevent hepatotoxicity. Monitor respiratory depression, especially in opioid-naive patients and those with sleep apnea. Use with caution in hepatic impairment, ethanol use disorder, and in patients on other CNS depressants. Administer with food to reduce GI upset.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
Do not exceed recommended dose; too much acetaminophen can cause liver damage.,Avoid alcohol while taking this medication.,Do not combine with other acetaminophen-containing products.,May cause drowsiness or dizziness; avoid driving or operating machinery.,Take with food or milk if stomach upset occurs.,Report any difficulty breathing, severe constipation, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.,Do not stop suddenly after prolonged use to avoid withdrawal symptoms.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MYCITE KIT vs SEDAPAP, answered by our medical review team.
ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. SEDAPAP is a Barbiturate Combination Analgesic that works by SEDAPAP is a combination of an opioid agonist (acetaminophen, hydrocodone) and a non-opioid analgesic. Hydrocodone acts as a mu-opioid receptor agonist, inhibiting ascending pain pathways and altering pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and providing analgesia and antipyresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MYCITE KIT and SEDAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. The standard adult dose of SEDAPAP is: 1-2 tablets (acetaminophen 325 mg/butalbital 50 mg/caffeine 40 mg) orally every 4 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MYCITE KIT and SEDAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. SEDAPAP is classified as Category C. First trimester: Increased risk of neural tube defects and orofacial clefts (valproate component). Second and third trimesters: Fetal valproate syndrome (craniofacial abnormalities. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.